Skip to content

Mesoblast Ltd Price, Chart & Factor Analysis

Free Data & Analytics Access

Next earnings: Wed, Nov 25, 2026, before the market opens · estimates and history

Mesoblast Ltd · E.MSB.AU · Australia
Use symbol E.MSB.AU in our API & Excel add-in to retrieve this data ↓
1.70
(-0.01%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum -100%
Trend -100%
Bubble Risk LOW
Realised Volatility (20D) 97.67%

Mesoblast Ltd Forecast

Mesoblast Ltd short-term momentum is strongly negative (up over 0 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term SELL signal. The long-term trend is strongly negative (0 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 97.7% a year, a typical one-standard-deviation range is 1.4618–1.9282 over a week, 1.2171–2.1729 over a month and 0.0396–3.3504 over a year. (Signals as of 21 Nov 2026.)

Mesoblast Ltd Price Chart

MacroFinance.ai
Market/MacroIndicatorNowChangeRange
Quantitative
Mesoblast Ltd
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Mesoblast Ltd
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Mesoblast Ltd
Signal
0
ⓘLatest reading of Signal.
Teal = supportive for Mesoblast Ltd, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Research on Mesoblast Ltd

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Mesoblast Ltd Trading Strategies

31 backtested tactical asset allocation strategies hold EFA (developed markets outside the US), the closest tradable exposure to Mesoblast Ltd; 22 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

See all 31 strategies holding EFA →

Statistical Distribution of Returns

Plus

How Mesoblast Ltd’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Mesoblast Ltd behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Mesoblast Ltd (Australia)

Mesoblast Ltd is a listed security in Australia. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Mesabi Trust

Frequently asked questions

What is Mesoblast Ltd?
Mesoblast Ltd is a listed security in Australia. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Mesoblast Ltd price?
The latest close is 1.695 (21 Nov 2026), -0.01% on the day. The price at the top of the page refreshes during the trading day.
Is Mesoblast Ltd in an uptrend?
As of 21 Nov 2026, short-term momentum is strongly negative (0 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly negative (0 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Mesoblast Ltd?
20-day realised volatility is 97.7% a year (21 Nov 2026), which implies a typical one-standard-deviation move of about 28.2% over a month and 13.8% over a week.
What factors affect Mesoblast Ltd?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Mesoblast Ltd, grouped as Quantitative Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Mesoblast Ltd?
31 backtested tactical asset allocation strategies trade Mesoblast Ltd through EFA; 22 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Mesoblast Ltd returns analysed?
The Statistical Distribution of Returns section shows the distribution of Mesoblast Ltd daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Mesoblast Ltd historical data?
In the Free historical data section of this page: the last 10 years of Mesoblast Ltd daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Mesoblast Ltd historical data (last 10 years)

Browse or instantly download the last 10 years of Mesoblast Ltd daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.MSB.AU&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-201.695
2026-11-191.705
2026-11-181.76
2026-11-171.795
2026-11-161.885
2026-11-131.93
2026-11-121.955
2026-11-112.03
2026-11-102.08
2026-11-092.04
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.